20487-10-9

Usage

InChI:InChI=1/C8H8O2/c1-6-3-2-4-7-8(6)10-5-9-7/h2-4H,5H2,1H3

Upstream product

• 75-09-2 dichloromethane 
• 488-17-5 3-methylbenzene-1,2-diol 
• 74-97-5 chlorobromomethane 
• 74-95-3 1,1-dibromomethane 

Downstream Products

• 17367-93-0 4,5-(methylenedioxy)indole 
• 196091-24-4 5-Amino-4-methyl-1,3-benzodioxole 

Relevant academic research and scientific papers

A re-examination of the methylenation reaction

A re-examination of the methylenation reaction of 1-hydroxy-2-mercapto-, 1,2-dihydroxy- and 1,2-dimercapto-substituted benzenes by bromochloromethane with cesium carbonate shows that these substrates give mixtures of five- and ten-membered benzocondensed heterocyclic compounds and in some cases even dibenzodioxines.

2-IMIDAZOLINYLAMINO HETEROCYCLIC COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS

The subject invention relates to compounds having the structure: STR1 wherein (a) n is an integer from 1 to about 3; (b) X and Y are each independently selected from O, S and CH 2, with at least one of X and Y being O or S;(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and(d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

A convenient procedure for the synthesis of 1-tetralone dertivatives using a Suzuki coupling-Friedel-Crafts acylation sequence

The reported 1-tetralone derivatives have been synthesized from arylbromides using as keys steps a Suzuki coupling followed by intramolecular Friedel-Crafts acylation.

Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies

A method of using pyrazolyl benzenesulfonamide compounds in treating inflammation and inflammation-related disorders in companion animals is disclosed.

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: STR1 or a pharmaceutically-acceptable salt thereof.

2-IMIDAZOLINYLAMINO HETEROCYCLIC COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS

The subject invention relates to compounds having the structure: STR1 wherein (a) n is an integer from 1 to about 3; (b) X and Y are each independently selected from O, S and CH 2, with at least one of X and Y being O or S;(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and(d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating one or more of respiratory disorders, ocular disorders, and gastrointestinal disorders.

Circulation-active dioxyalkylenearyl-dihydropyridines

Circulation-active dihydropyridines of the formula STR1 in which R1 is H, CN, NO2 or --COOR7, R7 is H, alkyl or various other radicals, R2 and R4 each independently is alkyl or other radicals, R3 is H or optionally substituted alkyl, and R5 completes a keto or ester group, and physiologically acceptable salts thereof. Also the aldehyde intermediate therefor of the formula STR2

Circulation-active dioxyalkylenearyl-dihydropyridines

Circulation-active dihydropyridines of the formula STR1 in which R1 is H, CN, NO2 or --COOR7, R7 is H, alkyl or various other radicals, R2 and R4 each independently is alkyl or other radicals, R3 is H or optionally substituted alkyl, R5 completes a keto or ester group, and R6 is a direct bond or --CF2 -- or --CHF--, and physiologically acceptable salts thereof.

Structure-Activity Relationships in Potentially Hallucinogenic N,N-Dialkyltryptamines Substituted in the Benzene Moiety

A series of N,N-dialkyltryptamines with methylthio or methylenedioxy substituents in the 4, 5, and 6 positions and methyl or isopropyl on the side-chain nitrogen has been synthesized.The behavioral pharmacology of these compounds showed them to posses Bovet-Gatti profiles characteristic of hallucinogens, and the 5-methylthio congener was the most potent.Binding studies at LSD and 5-HT sites demonstrated that no single structural feature correlated with binding or behavioral changes and suggest a complex mode of action for these potential hallucinogenic agents.